Simplex Trading’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-2,200
| Closed | -$4K | – | 10410 |
|
|
2023
Q1 | $4K | Buy |
+2,200
| New | +$2.73K | ﹤0.01% | 8258 |
|
|
2022
Q4 | – | Sell |
-1,900
| Closed | -$4K | – | 10920 |
|
|
2022
Q3 | $4K | Buy |
+1,900
| New | +$6.73K | ﹤0.01% | 9014 |
|
|
2022
Q2 | – | Sell |
-3,300
| Closed | -$22K | – | 11532 |
|
|
2022
Q1 | $22K | Sell |
3,300
-500
| -13% | -$3.56K | ﹤0.01% | 8180 |
|
|
2021
Q4 | $31K | Buy |
3,800
+2,800
| +280% | +$23.1K | ﹤0.01% | 7883 |
|
|
2021
Q3 | $6K | Hold |
1,000
| – | – | ﹤0.01% | 9247 |
|
|
2021
Q2 | $6K | Buy |
+1,000
| New | +$8.31K | ﹤0.01% | 9428 |
|
|
2021
Q1 | – | Sell |
-171
| Closed | -$119K | – | 10384 |
|
|
2020
Q4 | $119K | Buy |
171
+117
| +217% | +$911 | ﹤0.01% | 5270 |
|
|
2020
Q3 | $44K | Sell |
54
-103
| -66% | -$639 | ﹤0.01% | 5736 |
|
|
2020
Q2 | $108K | Sell |
157
-96
| -38% | -$518 | ﹤0.01% | 4723 |
|
|
2020
Q1 | $120K | Buy |
253
+132
| +109% | +$760 | ﹤0.01% | 4178 |
|
|
2019
Q4 | $105K | Buy |
121
+56
| +86% | +$303 | ﹤0.01% | 4473 |
|
|
2019
Q3 | $21K | Buy |
+65
| New | +$260 | ﹤0.01% | 5795 |
|
|
2019
Q2 | – | Sell |
-116
| Closed | -$71K | – | 8035 |
|
|
2019
Q1 | $71K | Buy |
116
+69
| +147% | +$333 | ﹤0.01% | 4695 |
|
|
2018
Q4 | $15K | Buy |
47
+34
| +262% | +$159 | ﹤0.01% | 5589 |
|
|
2018
Q3 | $8K | Sell |
13
-56
| -81% | -$416 | ﹤0.01% | 6559 |
|
|
2018
Q2 | $52K | Sell |
69
-122
| -64% | -$1.76K | ﹤0.01% | 5015 |
|
|
2018
Q1 | $40K | Buy |
+191
| New | +$4.24K | ﹤0.01% | 2671 |
|
Other funds holding JNCE
Simplex Trading's JNCE Position: Q2 2023 in Review
Simplex Trading sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 3,373 shares — an estimated $6K sold.
Simplex Trading first reported a position in JNCE in Q4 2017 and held it in 13 quarters. The position peaked at $354K in Q3 2018. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Simplex Trading reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Simplex Trading sold 3,373 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $6K.
- Simplex Trading first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2017 and held it in 13 quarters.
- Simplex Trading's Jounce Therapeutics, Inc. Common Stock position peaked at $354K in Q3 2018.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Simplex Trading's 13F filing for Q2 2023, filed 4 Aug 2023.